Fruquintinib: First Global Approval.
Fruquintinib (Elunate®) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours. In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies. Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer. This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.